Y. Peter Li, Ph.D., M.B.A.
Co-Founder, and Executive Chairman
Yishan (Peter) Li, Ph.D., M.B.A. is co-founder of Turning Point Therapeutics, Inc. (Turning Point), a clinical-stage biotech company, listed on NASDAQ (Ticker: TPTX). In June 2022, Bristol Myers Squibb announced the acquisition of Turning Point for $4.1 billion. Dr. Li served as Chairman and CEO of Turning Point from October 2013 (founding) to September 2018 and continued to serve as a Director until Turning Point completed a successful $191 million IPO on Nasdaq in April 2019. As Chairman and CEO, Dr. Li led Turning Point for 5 years and successfully raised 4 rounds of venture financing for $147 million, in total, from leading biotech investors, Cormorant Asset Management, OrbiMed, S.R. One, Lilly Asia Ventures, Foresite Capital, venBio, HBM Partners, Nextech Invest, etc. Turning Point has built a strong pipeline with the lead compound Repotrectinib entering pivotal Phase 2 clinical trial and two additional projects in clinical development (TPX-0022, TPX-0046). On November 15, 2023, FDA approves Repotrectinib (AUGTYROTM) for locally advanced or metastatic ROS1+ NSCLC.
Prior to Turning Point, Dr. Li served as Executive Vice President at Epitomics, Inc., a leading antibody technology company specializing in rabbit monoclonal antibody development for reagent, diagnostics, and therapeutics (acquired by Abcam, plc in March 2012). Prior to Epitomics, Dr. Li was Vice President at Kenson Ventures, LLC. He served on Board of Directors and observers to the Board for biotech companies.
Dr. Li was a postdoctoral research fellow at the Department of Molecular and Cell Biology, University of California, Berkeley. He earned his M.B.A. from Haas School of Business, University of California, Berkeley. He received his Ph.D. in biochemistry from Ohio State University, where he was a University Presidential Fellow, and his B.S. from University of Science and Technology of China. Dr. Li was an honoree for the Committee of 100 Circle of Excellence Award in Humanity in Science & Technology in 2023.